Urothelial Carcinoma: Bladder and Upper Tract

Urothelial (transitional cell) carcinoma is the predominant cancer of the urinary tract lining, which extends from the renal calyces and pelvis down the ureters to the bladder and proximal urethra. The great majority of cases arise in the bladder, but the same urothelium can give rise to upper tract tumours of the renal pelvis and ureter. A defining feature of the disease is its tendency to recur and to appear at multiple sites along the urinary tract.

Definition

Urothelial carcinoma is a malignant epithelial neoplasm of the urothelium lining the urinary tract, occurring most often in the bladder and less commonly in the renal pelvis and ureter (upper tract urothelial carcinoma), classified by stage (non-muscle-invasive vs muscle-invasive) and grade.

Scope

This entry covers the epidemiology, risk factors, and classification of urothelial carcinoma of the bladder and upper urinary tract: the distinction between non-muscle-invasive and muscle-invasive bladder cancer, tumour grade, and the field-change concept that underlies multifocality and recurrence. It is a reference-educational overview and does not provide diagnostic or treatment recommendations.

Core questions

• What distinguishes non-muscle-invasive from muscle-invasive bladder cancer?
• What are the major risk factors for urothelial carcinoma?
• Why do urothelial tumours tend to be multifocal and to recur?
• How do upper tract urothelial carcinomas differ from bladder tumours?

Key concepts

• Non-muscle-invasive bladder cancer (NMIBC)
• Muscle-invasive bladder cancer (MIBC)
• Carcinoma in situ
• Tumour grade (low vs high)
• Upper tract urothelial carcinoma (UTUC)
• Painless haematuria as a presenting sign
• Field cancerisation and multifocality

Mechanisms

The urothelium is exposed along its whole length to carcinogens excreted in the urine, which is thought to contribute to a field effect in which multiple, often metachronous, tumours arise—accounting for the multifocality and high recurrence rate of the disease (Sanli, 2017). Bladder tumours are broadly divided into a papillary, frequently recurring but lower-risk non-muscle-invasive group and a muscle-invasive group with greater metastatic potential, a distinction reflected in their molecular profiles. Histological classification and grading follow the WHO scheme (Humphrey, 2016).

Clinical relevance

Painless visible haematuria is the most common presenting feature of urothelial carcinoma and is the symptom that typically prompts investigation of the urinary tract (Lenis, 2020). The classification of a tumour as non-muscle-invasive or muscle-invasive, together with its grade, is central to how the disease is described and to the intensity of subsequent surveillance. This entry describes how the disease is classified and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Bladder cancer is among the more common cancers worldwide and is substantially more frequent in men than in women (Bray, 2024). Cigarette smoking is the single most important risk factor; occupational exposure to aromatic amines (historically in the dye, rubber, and chemical industries) is also well established, and in some regions chronic infection with Schistosoma haematobium is associated with squamous cell bladder cancer (Sanli, 2017; Lenis, 2020). Upper tract urothelial carcinoma is much rarer and has additional associations, including aristolochic acid exposure and Lynch syndrome.

Evidence & guidelines

Histological classification and grading follow the WHO classification of tumours of the urinary system and male genital organs (Humphrey, 2016), and anatomical extent is described by the TNM staging system. Disease-specific guidelines for bladder and upper tract urothelial carcinoma are published by professional bodies such as the European Association of Urology and the American Urological Association; readers should consult the current versions.

Seminal works

• sanli-2017
• lenis-2020
• humphrey-2016

Frequently asked questions

What is the difference between non-muscle-invasive and muscle-invasive bladder cancer?

Non-muscle-invasive tumours are confined to the urothelium and lamina propria and tend to recur but less often spread, whereas muscle-invasive tumours have grown into the bladder muscle wall and carry a higher risk of metastasis; the distinction shapes how the disease is classified and surveilled.

Why does bladder cancer often come back?

The entire urothelial lining is exposed to urinary carcinogens, producing a field effect in which new tumours can arise at multiple sites over time, which is why urothelial carcinoma is characteristically multifocal and recurrent.